Loss of response to melatonin treatment is associated with slow melatonin metabolism
- PMID: 20576063
- DOI: 10.1111/j.1365-2788.2010.01283.x
Loss of response to melatonin treatment is associated with slow melatonin metabolism
Abstract
Background: In some of our patients with intellectual disability (ID) and sleep problems, the initial good response to melatonin disappeared within a few weeks after starting treatment, while the good response returned only after considerable dose reduction. The cause for this loss of response to melatonin is yet unknown. We hypothesise that this loss of response is associated with slow melatonin metabolism.
Method: In this study, we determined melatonin clearance in two female (aged 61 and 6 years) and one male (aged 3 years) patients who had chronic insomnia, late melatonin onset and mild ID, and whose sleep quality worsened a few weeks after initial good response to melatonin treatment, suggesting melatonin tolerance. After a 3-week washout period, patients received melatonin 1.0, 0.5 or 0.1 mg, respectively. Salivary melatonin level was measured just before melatonin administration, and 2 and 4 h thereafter. After this melatonin clearance test, melatonin treatment was resumed with a considerably lower dose.
Results: In all patients melatonin concentrations remained >50 pg/mL at 2 and 4 h after melatonin administration. After resuming melatonin treatment sleep problems disappeared. The same procedure was followed in three patients who did not show loss of response to melatonin after 6 months of treatment. In all patients in the control group melatonin concentrations decreased between 2 and 4 h after melatonin administration with a mean of 83%.
Conclusion: We hypothesise that loss of response to melatonin treatment can be caused by slow metabolisation of exogenous melatonin. As melatonin is metabolised in the liver almost exclusively by cytochrome P450 enzyme CYP1A2, this slow melatonin metabolism is probably due to decreased activity/inducibility of CYP1A2. In patients with loss of response to melatonin, a melatonin clearance test should be considered and a considerably dose reduction is advised.
Similar articles
-
Melatonin decreases daytime challenging behaviour in persons with intellectual disability and chronic insomnia.J Intellect Disabil Res. 2010 Jan 1;54(1):52-9. doi: 10.1111/j.1365-2788.2009.01223.x. Epub 2009 Nov 2. J Intellect Disabil Res. 2010. PMID: 19888921 Clinical Trial.
-
Melatonin treatment in individuals with intellectual disability and chronic insomnia: a randomized placebo-controlled study.J Intellect Disabil Res. 2008 Mar;52(Pt 3):256-64. doi: 10.1111/j.1365-2788.2007.01016.x. J Intellect Disabil Res. 2008. PMID: 18261024 Clinical Trial.
-
Melatonin for chronic insomnia in Angelman syndrome: a randomized placebo-controlled trial.J Child Neurol. 2008 Jun;23(6):649-54. doi: 10.1177/0883073808314153. J Child Neurol. 2008. PMID: 18539989 Clinical Trial.
-
Melatonin and sleep disorders associated with intellectual disability: a clinical review.J Intellect Disabil Res. 2007 Jan;51(Pt 1):2-13. doi: 10.1111/j.1365-2788.2006.00893.x. J Intellect Disabil Res. 2007. PMID: 17181598 Review.
-
The role of melatonin and circadian phase in age-related sleep-maintenance insomnia: assessment in a clinical trial of melatonin replacement.Sleep. 1998;21(1):52-68. Sleep. 1998. PMID: 9485533 Review.
Cited by
-
Melatonin, a natural antioxidant therapy in spinal cord injury.Front Cell Dev Biol. 2023 Aug 25;11:1218553. doi: 10.3389/fcell.2023.1218553. eCollection 2023. Front Cell Dev Biol. 2023. PMID: 37691830 Free PMC article. Review.
-
Understanding patient characteristics and medication prescriptions in children with mental health and neurodevelopmental disorders referred to a sleep clinic-A quality improvement/quality assurance analysis.Front Psychiatry. 2022 Nov 10;13:878356. doi: 10.3389/fpsyt.2022.878356. eCollection 2022. Front Psychiatry. 2022. PMID: 36440388 Free PMC article.
-
Is Melatonin the "Next Vitamin D"?: A Review of Emerging Science, Clinical Uses, Safety, and Dietary Supplements.Nutrients. 2022 Sep 22;14(19):3934. doi: 10.3390/nu14193934. Nutrients. 2022. PMID: 36235587 Free PMC article. Review.
-
A study of the mechanism of small-molecule soybean-protein-derived peptide supplement to promote sleep in a mouse model.RSC Adv. 2020 Mar 18;10(19):11264-11273. doi: 10.1039/d0ra00389a. eCollection 2020 Mar 16. RSC Adv. 2020. PMID: 35495343 Free PMC article.
-
Efficacy and safety of supplemental melatonin for delayed sleep-wake phase disorder in children: an overview.Sleep Med X. 2020 Aug 19;2:100022. doi: 10.1016/j.sleepx.2020.100022. eCollection 2020 Dec. Sleep Med X. 2020. PMID: 33870175 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials